Nanexa AB: Nanexa doses first patient in the 30 mg dose group in the Phase I study with NEX-22
Nanexa AB announces today that the first patient has been dosed in the 30 mg dose group in the ongoing Phase I study with NEX-22, the company's one-month formulation of liraglutide. The ongoing Phase ...
Hims & Hers: AI-Powered Healthcare Disruption
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...
News-Medical.Net on MSN11 時間
Tirzepatide helps people without diabetes lose 13% body weight in real-world study
A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...
Modern Healthcare12 日
Digital health companies see opportunity in regulatory upheaval
Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...
How drugs like Wegovy might affect kids in the long term
The number of teens and young adults taking GLP-1 drugs has increased by 594 percent—but scientists are still trying to ...
Lexaria Bioscience Corp.: The Global Revolution in Healthcare Driven by GLP-1 Drugs and the ...
Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.